Skip to content
You are now leaving to visit

Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

Favorable safety and tolerability were observed P rimary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD, Calif. , Jan. 28, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc.